Navigation Links
Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Date:8/19/2007

NEW YORK, Aug. 9 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and inflammatory diseases, announced today the addition of two sites to its Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine carcinoma (advanced carcinoid cancer). With the addition of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, 676 N. St. Clair Street, Suite 850, Chicago, IL and the H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, the Phase II clinical trial is presently being conducted in seven sites. The principal investigator for Northwestern is Mary Mulcahy, MD, and the principal investigator for Lee Moffitt is Larry K. Kvols, M.D.

"The addition of these two major cancer centers to the Phase II trial of Atiprimod in advanced carcinoid patients signifies our continuing commitment to facilitate rapid enrollment of this trial," said Dr. Gary S. Jacob, Chief Executive Officer of Callisto. "Both sites are active in the treatment of neuroendocrine cancers, and have built significant reputations within the carcinoid community, which should substantially enhance the pace of enrollment and increased accessibility to prospective patients interested in participating in this trial." Currently Callisto has enrolled 31 patients of the 40 subjects planned for this Phase II clinical trial.

The primary objective of the Phase II clinical trial is to evaluate efficacy of Atiprimod in patients with low to intermediate grade neuroendocrine carcinoma who have metastatic or unresectable cancer and who have progression of their disease despite standard therapy (octreotide). Patients, after signing an informed consent, are required to complete two weeks of a symptoms diary to establish their symptoms baseline before commencing Atiprimod dosing. A maximum of 40 evaluable patients will be enrolled in th
'/>"/>

SOURCE Callisto Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
2. Callisto Intends to Move Guanilib into Clinical Trials in Ulcerative Colitis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014  The management team at Columbia Laboratories, ... a conference call on July 31, 2014, to ... June 30, 2014.  The call details are as ... am EDTDial-in numbers: , Toll free: (877) 870-4263 ... & archive): , www.columbialabs.com , under ,Investor, ...
(Date:7/23/2014)... -- Global healthcare company GSK reports Q2 ... increased price competition and supply disruptions to its Consumer ... points out that the company is very much in transition, ... confident about long-term prospects as well as the investments ... Simon Dingemans adds that the company is ...
(Date:7/23/2014)... Research and Markets has ... Kits and Trays - Global Strategic Business Report" ... http://photos.prnewswire.com/prnh/20130307/600769 This report ... and Trays in US$ Thousands by the following ... Custom Basin Kits, Custom Ob/Gyn Kits, General Delivery ...
Breaking Medicine Technology:Columbia Laboratories to Discuss Second Quarter 2014 Financial Results on July 31st Conference Call 2Prepackaged Medical Kits and Trays - Global Strategic Business Report: Updated 2014 Report 2
... When you,re producing 1.8 million baked ... crucial for brand confidence and sustained business growth. ... and other popular savouries and snacks has further enhanced ... Digitron Instrumentation Ltd. Pork Farms is a ...
... 2011 Labor and management in the biopharmaceutical industry ... increased protections to fight intellectual property theft, counterfeiting and ... protections." In a resolution unanimously ... Association ( PILMA ), the group applauds the ongoing ...
Cached Medicine Technology:Temperature Monitoring Device From Digitron Helps Pork Farms Take a Big Bite of the Food Market 2Temperature Monitoring Device From Digitron Helps Pork Farms Take a Big Bite of the Food Market 3PILMA Vows to 'Redouble' Support for Increased Protections Against Intellectual Property Theft 2
(Date:7/23/2014)... on human cancer genes have been focused on the ... be translated in the form of amino acids thus ... regulatory region or activator which controls the expression and ... was known of the role exerted such DNA fragment ... in Nature in collaboration with the group ...
(Date:7/23/2014)... Irvine, Calif., July 23, 2014 A therapy combining ... of a gene inhibitor into the brain restored voluntary ... UC Irvine,s Reeve-Irvine Research Center have found. , In ... achieved this breakthrough by turning back the developmental clock ... corticospinal tract nerve connections and providing a scaffold so ...
(Date:7/23/2014)... This report defines and segments the ... the Middle East & Africa, and Americas) - Global ... with analysis and forecasts of the global revenue. The ... over $10 billion in 2014 to nearly $14 billion ... , browse 49 Market Tables and 10 Figures Spread ...
(Date:7/23/2014)... A Forever Recovery, an open-ended drug and ... great start and gives them a solid foundation in ... Internet Addiction section of its website at http://aforeverrecovery.com/behavioral-addictions/internet-addiction/ ... Internet addiction is not just as legitimate a disorder ... trapping more and more victims each year – particularly ...
(Date:7/23/2014)... Children and teens who lose a parent might face an ... study suggests. People who were children or teens when ... death during the study period than those who had not ... Although the study found an association between a parent,s ... wasn,t designed to prove cause-and-effect. Also, the increased risk ...
Breaking Medicine News(10 mins):Health News:Gene inhibitor, salmon fibrin restore function lost in spinal cord injury 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 2Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 3Health News:EHV Transmission Market $14 Billion by 2019 - Report by MarketsandMarkets 4Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:Parent's Death May Raise Risk of Early Death for Grown Children, Study Suggests 2
... significantly slow or halt science's ability to establish ... by industry, a team of scientists and lawyers ... caution that litigation's effects could seriously impair efforts ... variety of diseases, including Parkinson's disease, Alzheimer's disease ...
... blood flow to the brain, helps the bodies detoxify ... Alzheimer's, say researchers. ,"Exercise improves thinking and mental ... associate professor of medicine at the New York University ... Health Central. ,"Studies have shown that it works ...
... and PRK eye procedures are safe and effective, according ... recent American Academy of Ophthalmology’s //Joint Meeting. ,Researchers ... PRK treatments say both procedures provide stable, long term ... answer to those who doubt LASIK’s reliability, showing that ...
... big, juicy steak for dinner last night, adding a large amount ... For one in ten of us, that could be a big ... our diet, our bodies use it for energy. But patients with ... of Americans – are more likely to develop arthrosclerosis, or build-up ...
... the age when reading a newspaper means holding ... glasses, wavefront-optimized //lens technology may offer a better ... American Academy of Ophthalmology’s 2006 Joint Meeting. ... lenses developed using wavefront technology offer significant improvements ...
... Blaming the resurfacing of polio cases in the Indian ... //Delhi Chief Minister Sheila Dikshit Saturday said that around ... part of the Pulse Polio programme. ,"Delhi was ... occurrence of fresh cases, mostly due to migration of ...
Cached Medicine News:Health News:Fast-Multiplying Lawsuits Can Stymie Medical Science, Authors Warn 2Health News:Fast-Multiplying Lawsuits Can Stymie Medical Science, Authors Warn 3Health News:PRK and LASIK Surgeries ‘Safe and Effective 2Health News:Sugars in Liver Found to Clear Fats from the Bloodstream 2Health News:Beyond Bifocals: Wavefront Technology Benefits Patients With Presbyopia 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: